CASI Pharmaceuticals, Inc. · OTC:CASIF
CASI Pharmaceuticals — Investor Presentation (October 2017)
17 slides from CASI Pharmaceuticals's investor presentation, October 2017
Slide 1: Partnering Presentation
CASI Pharmaceuticals Partnering Presentation
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statement
Slide 3: Corporate Presentation
Corporate Presentation • Company Overview • Leveraging China’s Biopharmaceutical Market • Structure for Partnering in China • CASI’s In-Licensing & Partnering Goals Slide 3
Slide 4: Company Overview
Company Overview CASI is a biopharmaceutical company focused on the acquisition, development, and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market, with a focus on delivering innovative drugs to China NASDAQ-listed U.S. company headqu
Slide 5: A Seasoned, Bi-Cultural Board & Management Team
A Seasoned, Bi-Cultural Board & Management Team BOARD OF DIRECTORS Dr. Wei-Wu He, Chairman IDG-ACCEL China Fund Venture Partner; Chairman & CEO, OriGene Technologies, Inc. Dr. Quan Zhou Founder, Managing Director and General Partner at IDG Capital Partners James Huang General Partner, Kleiner Perkin
Slide 6: Scientific/Clinical Advisors
Scientific/Clinical Advisors Dr. Tak W. Mak, Lead Scientific Advisor Dr. Mak served as a Director of the Company from February 2012 – May 2016. Dr. Mak is currently the Director of the Campbell Family Institute for Breast Cancer Research at the Princess Margaret Hospital and a University Professor i
Slide 7: Corporate Structure
Corporate Structure Beijing P.R. China Rockville, Maryland USA Beijing R&D Center Corporate Headquarters - Discovery Research - Clinical Development - Regulatory Affairs - Business Development - Clinical Development - Finance - Business Development - Corporate Administration - Financing - Legal - Co
Slide 8: CASI's Core Competencies
CASI’s Core Competencies • Expertise in oncology drug development/regulatory process and filings with the CFDA Strong relationships with CFDA 5 CTAs filed with CFDA over past 2 years 4 approvals, each within 12 months • Conducting clinical trials in China in full compliance with ICH GCP and CF
Slide 9: China Market Opportunity
China Market Opportunity • China’s pharmaceutical market is expected to grow 14-17% per annum, reaching $170 billion and becoming the 2nd largest market in the world by 2017 • Oncology is the largest, global therapeutic market overall, exceeding $100 billion in 2014 • CASI leverages its expertise an
Slide 10: Regulatory Pathways for Drug Registration in China
Regulatory Pathways for Drug Registration in China Slide 10
Slide 11: CASI's China Development & Commercialization Strategy
CASI’s China Development & Commercialization Strategy • Employ either an import drug registration path, a global development program or local development approach for registration and commercialization of products in China • Conduct clinical trials in China as part of or in parallel with partners’ m
Slide 12: Structure for a China Partnership
Structure for a China Partnership • License between Licensor and CASI Pharmaceuticals for the development and commercialization of drug in China • exclusive rights to CASI for China, including Taiwan, Hong Kong, and Macau • CASI responsible for all development, registration and commercialization cos
Slide 13: Licensing Agreements
Licensing Agreements • In September 2014, CASI entered into licensing agreement with Spectrum Pharmaceuticals (Nasdaq: SPPI) for China development and commercialization • Exclusive rights to three commercial oncology drugs • ZEVALIN® – Treatment of non-Hodgkin’s Lymphoma • MARQIBO® – Treatment of ac
Slide 14: Business Development Goals
Business Development Goals CASI’s Business Development Objectives In-license innovative, targeted therapeutics for cancer and other unmet medical needs for development, registration and commercialization in China Partner ENMD-2076 for regional development and commercialization outside of China a
Slide 15: Partnership Objectives
Partnership Objectives Strategic partnership for developing and commercializing innovative therapeutics in China, including Taiwan, Hong Kong and Macau • Leverage CASI’s expertise and resources for the development and commercialization of innovative products in China • Opportunity to gain earlier ma
Slide 16: CASI Pharmaceuticals A Unique Integrated Business Model
CASI Pharmaceuticals A Unique Integrated Business Model Model - Compelling business model with important North America/China synergies and competitive advantage with efficiency and effectiveness for drug development and commercialization. Market - Well-positioned to pursue significant and unpreceden
Slide 17: NASDAQ: CASI www.casipharmaceuticals.com
NASDAQ: CASI www.casipharmaceuticals.com
CASI Pharmaceuticals — Investor Presentation (October 2017) on 6ix